Ultragenyx Sells Additional 25% Crysvita Royalty Interest to OMERS for $400 Million
Ultragenyx Pharmaceutical Inc. has announced the sale of an additional 25% of its royalty interest in future North American sales of Crysvita® (burosumab) to OMERS Life Sciences for $400 million. This non-dilutive financing agreement will provide Ultragenyx with immediate capital to support four anticipated product launches and strengthen its balance sheet. Under the new agreement, OMERS will begin receiving the additional 25% royalty interest on net sales of Crysvita in the U.S. and Canada starting in January 2028. The total payments to OMERS under this and the previous 2022 agreement are capped at 1.55 times the purchase price. OMERS will continue to receive 30% of Crysvita net sales in North America following the achievement of the 2022 agreement's cap.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568671-en) on November 04, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。